

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION



The Official Publication of the Asian Pacific Organization for Cancer Prevention and Control and the UICC Asia Regional Office for Cancer Control
An Official Journal of the International Association of Cancer Registries



Volume 9, Number 1, 2008



APOCC Areas

Australia

Central Asia

China

Japan

Korea

South Asia

South-East Asia

Taiwan Area



Education

Epidemiology

<http://www.apnep.org>

Screening and Intervention

Toxicological Pathology



Editorial Board

Editor-in-Chief

Alireza Mosavi Jarrahi, MSPH, Ph.D.

Associate Prof. of Epidemiology President, Asian Pacific Organization for Cancer Prevention
Associate Prof. Of Epidemiology
Dept of Social Medicine, Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
rmosaviyahoo.com

Honorary Editor-in-Chief

Malcolm Anthony Moore, Ph.D.

Toxicologist Director-Coordination, Asia Pacific Organization for Cancer Prevention, Korean Cancer Center, Goyang, Korea./ apocpcontrol@gmail.com

Associate Editor

Prof. David Roder

Professor of Cancer Epidemiology Chair Cancer Epidemiology and Population Health, Beat Cancer Project, University of South Australia, Adelaide, Australia
ca.linkedin.com/in/david-roder-54699329
roderinternode.on.net

Dr. Abhishek Shankar

Preventive Oncology, Radiation Oncology Assistant Professor
Department of Preventive Oncology,
Dr B R Ambedkar Institute Rotary Cancer Hospital
All India Institute of Medical Sciences,
Delhi, India
doc.abhishankargmail.com

Founder

Yip Cheng-Har, MD, FACS

Surgery Prof. of Gynaecological Oncology
Faculty of Medicine, University Tunku Abdul Rahman, Kuala Lumpur, Malaysia
chenghar.yip@gmail.com

Keun-Young Yoo, MD, Ph.D.

Prof. of Cancer Epidemiology President, APOCP
President, Armed Forces Capital Hospital
Professor, Seoul National University College of Medicine, Seoul, Korea
bkkyoo@gmail.com

Kazuo Tajima, MD

Pathology Prof. of Pathology
Director, Aichi Cancer Center Research Institute, Ozaka, Japan
ktajimaclin.medic.mie-u.ac.jp

Prof. You Lin Qiao, M.D. Ph.D.,

Epidemiology Director, Dept. of Cancer Epidemiology
Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
qiaoycicams.ac.cn

International Advisory Board

Dr. Khuseynov Zafardzhon

Oncologist Director of the Republic Oncological Scientific Center, Ministry of public health, Republic of Tajikistan
zafhabmail.ru
+992907710535

Prof. Niveen Abu-Rmeileh

Community Medicine Associate prof. of Community Medicine
Institute of Community and Public Health,
Birzeit University,
Birzeit - Palestine
nrmeileh@gmail.com

Prof. Rema Gvamichava

Prof. of Surgery A. Gvamichava National Cancer Center,
Tbilisi State Medical University
Tbilisi, Georgia
doctorremayahoo.com

Prof. Mohammad Esmail Akbari

Prof. of Surgery Cancer Research Center,
Shahid Beheshti University of Medical Sciences, Tehran, Iran
profmeakbar@gmail.com

Dr. Mohsen Asadi-Lari

Prof. of Epidemiology Deputy for International Relations
Ministry of Health, Tehran, Iran
Prof. of Epidemiology, School of Public Health
Iran University of Medical Sciences, Tehran, Iran
mohsen.asadi@yahoo.com

Dr. Shahab Uddin

Cancer Biology Hamad Medical Corporation
Academic Health System
Doha, Qatar
suddinkhangmail.com

Prof. Goura Kishor Rath

Radiation Oncology Chief, DR BRAIRCH,
Professor, Department of Radiation Oncology, and
Head, National Cancer Institute,
AIIMS, Ansari Nagar, New Delhi-110029, India
gkrath2006@gmail.com

Dr. Farhana Badar

Cancer Registration and Epidemiology Sr. Biostatistician & Cancer Epidemiologist
Cancer Registry & Clinical Data Management
Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore, Pakistan
farhanaskm.org.pk

Prof. Kourosh Holakouie-Naieni

Epidemiology Professor in Epidemiology,
Department of Epidemiology, School of Health, Tehran University of Medical Sciences.
General Secretary, Iranian Epidemiological Association, Tehran, Iran
holakoikhotmail.com

Editorial Board

Prof. Jeff Dunn

Chief Executive Officer of Cancer Council Queensland.
School of Social Science, University of Southern Queensland, Queensland, Australia.
jeffdunnccancerqld.org.au

Dr. Xinen Huang

Prof. of Clinical Oncology Department of Oncology, Nanjing Medical University
Affiliated Cancer Hospital of Jiangsu Province; Nanjing, Jiangsu 210009, China.
huangxinen06163.com

Prof. Shahid Pervez

Histopathology Departments of Pathology & Laboratory Medicine
Faculty of Health Sciences, Medical College, The Aga Khan University, Karachi,
Pakistan.
shahid.pervezaku.edu

Prof. Salim M. Adib

Prof. of Public Health Professor of Public Health, American University of Beirut,
Beirut, Lebanon
WHO, East Mediterranean Regional Office
Nasr City, Cairo, Egypt
adibsemro.who.int

Dr. Anton Barchuk

Thoracic surgery Petrov Research Institute of Oncology
Saint Petersburg, Russian Federation
barchuk.antongmail.com

Prof. Murat Gultekin

Gynaecological Oncologist Sağlık Bakanlığı-Turkish Ministry of Health,
Hacettepe University, European Society of Gynaecological Oncology (ESGO)
www.linkedin.com/in/murat-gultekin-268136100
mrtgultekinyahoo.com

Prof. Abas Ghaderi

Cancer Immunologist Shiraz Institute for Cancer Research (A.G.), Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
ghaderi@gmail.com

DR. Elsayed I Salim

Faculty of Science, Tanta University, Tanta, Egypt
elsalem_777@yahoo.com

Dr. Reza Shirkohi

Medical Genetic Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
r_shirkohiyahoo.com

Prof. Mehrnoosh Doroudchi

Immunology Associate Professor of Immunology
Director of Memory T cell Laboratory
Department of Immunology, School of Medicine
Shiraz University of Medical Sciences, Shiraz-Iran
mdoroudsums.ac.ir

Prof. Manoochehr Makvandi

Virology Virology Dept. Ahwaz University of Medical Sciences, Ahwaz, Iran
manoochehrmakvandi29@yahoo.com

Prof. Jalal Pourahmad

Toxicologist School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

scholar.google.com/citations?user=SLqpnmoAAAAI&hl=en
pourahmad.jsbmu.ac.ir
0000-0002-4555-4168

Prof. Abolfazleh Movafagh

Genetic Dept. of Human genetic, Medical School
Shahid Beheshti University of Medical Sciences,
Tehran, Iran
movafagh.asbmu.ac.ir

Prof. Abdeladim Moumen

Molecular Virology and Biochemistry Head of R&D projects at Moroccan
Foundation for Advanced Science, Innovation and Research
RABAT, Morocco.

a.moumenmascir.com

Prof. Ravi Mehrotra

Cytopathology National Institute of Cancer Prevention and Research
WHO-FCCT Global Hub for information on smokeless tobacco products
(Institute of Cytology and Preventive Oncology-ICMR)
Department of Health Research, Noida, India
rmehrotraicmr.org.in

Prof. Abdulbari Bener

Epidemiology and biostatistics Dept. of Biostatistics & Medical Informatics,
Cerrahpaşa Faculty of Medicine, Istanbul University, Istanbul, TURKEY,
abdulbari.beneristanbul.edu.tr

Dr. Munir Abu-Helalah

Epidemiology Regional Director Middle East, North Africa and Central Asia
Global Academy for Health Sciences
Adjunct Associate Professor of Epidemiology and Preventive Medicine, Alfaisal
University, KSA
Consultant Chronic Diseases Control & Prevention and Medical Screening
mabuhelalahyadoo.co.uk

Prof. Nurbek Igissinov

Oncology Chairman of Public Association
Department of Surgical Diseases of Internship
Central Asian Cancer Institute
Astana Medical University
Astana, The Republic of Kazakhstan.
n.igissinov@gmail.com

Prof. Le Tran Ngoan

Occupational Health International University of Health and Welfare, Japan and
Hanoi Medical University, Viet Nam
letranngoanyahoo.com

Prof. Omran S. Habib

Social Medicine Department of Community Medicine, College of Medicine,
University of Basrah, Basrah, Iraq
omran49_basmedy@yahoo.com

Dr. Ammad Ahmad Farooqi

Senior Scientist | Institute of Biomedical and Genetic Engineering (IBGE), Islamabad
ammadfarooqirmclahore.com

Assistant Editor

Prof. Muhammad Asif Qureshi

Tumor Immunology Department of Pathology, Dow International Medical
College, Dow University of Health Sciences (OJHA CAMPUS), Karachi, Pakistan
www.unimedizin-mainz.de/tim/mitarbeiter.html
asifasifqureshi.com
+923002185053

Dr. Pravin Kesarwani

Molecular Genetic Radiation Oncology Research
William Beaumont Research Institute, USA
pravin.kesarwanigmail.com

Dr. Rahmatollah Moradzadeh

Epidemiology Assistant Professor
Department of Epidemiology, School of Public Health, Arak University of Medical
Sciences, Arak, Iran
moradzadehyahoo.com

Dr. Parastoo Hajian

Radiation Oncology Dept. of Radiotherapy, Medical School,
Shahid Beheshti University of Medical Sciences, Department of radiation oncology,
Shohad-e-Tajrish Hospital
parastoo.hajianyadoo.com

Dr. Constance Lay Lay Saw

Pharmaceutical Sciences Center for Cancer Prevention Research
Department of Pharmaceutics
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey, USA
constancesawgmail.com

Dr. Pratheeshkumar Poyil

Biotechnology Associate Scientist
King Faisal Specialist Hospital & Research Center
Riyadh, Saudi Arabia
ppratheeshkumargmail.com

Epidemiology (Etiologic studies of cancer)

International Advisory Board

Prof. Ali Montazeri

Public Health Health Metrics Research Center, Institute for Health Sciences
Research, ACECR, Iran
montazeriacecr.ac.ir
h-index: 65

Molecular and Cellular aspect (Inflammation, Oxidative stress, studies of cell lines)

Assistant Editor

Dr. Ajaz Ahmad Bhat

Cancer Biology Interim Translational Research Institute, Academic Health
System, Hamad Medical Corporation, Doha, Qatar
abhatsidra.org
000-0003-3640-6275

Editorial Board

Dr. Houssein Ghahramani

Biochemistry SBMU
ghahremanisbmu.ac.ir
Patient Care and Clinical aspect of Cancer

International Advisory Board

Prof. Mohammad Ali Mohagheghi

Surgen Deputy for Research, Iranian Academy of Medical Sciences, Tehran, Iran
mohagheghimiyahoo.com

Editorial Board

Dr. Ayesha AlRifai

Health Policy Arab American University & Birzeit University/Occupied Palestine.
a.alrifai1gmail.com

Assistant Editor

Farzad Taghizadeh-Hesary

Radiation Oncology Clinical Oncology Department, Shahid Beheshti University
of Medical Sciences, Iran
f_taghizadehsbmu.ac.ir

Volume & Issue: Volume 22, Issue 10, October 2021, Pages 3053-3404

1. COVID-19 Vaccination and Cancer, the Need for more Data

Pages 3053-3054

Seyed Alireza Javadinia; James S Welsh; Alireza Mosavi Jarrahi

[View Article](#) [PDF 201.52 K](#)

2. Opportunities and Challenges of Tobacco Control Policy at District Level in Indonesia: A Qualitative Analysis

Pages 3055-3060

Sepri Yunarman; Aries Munandar; Abdillah Ahsan; Ali Akbarjono; Dian Kusuma

[View Article](#) [PDF 655.82 K](#)

3. Association between Smokeless Tobacco Use and Risk of Periodontitis in Asian Countries: A Systematic Review and Meta-Analysis

Pages 3061-3074

Abhishek Mehta; Venkitachalam Ramanarayanan; Vineetha Karuveetil; Chandrashekar Janakiram

[View Article](#) [PDF 916.25 K](#)

4. Overexpression of c-Met is Associated with Poor Prognosis in Glioblastoma Multiforme: A Systematic Review and Meta-Analyses

Pages 3075-3080

Jellyca Anton; Sudibio Sudibio; Handoko Handoko; Tiara Bunga Mayang Permata; Henry Kodrat; Endang Nuryadi; Henry Sofyan; Eka Susanto; Rahmad Mulyadi; Renindra Ananda Aman; Soehartati Gondhowiardjo

[View Article](#) [PDF 372.31 K](#)

5. Factors Affecting Delayed Presentation and Diagnosis of Breast Cancer in Asian Developing Countries Women: A Systematic Review

Pages 3081-3092

Farida Briani Sobri; Adang Bachtiar; Sonar Soni Panigoro; Dumilah Ayuningtyas; Hardy Gustada; Patria Wardana Yuswar; Aqsha Azhary Nur; R. Cita Resti Anantia Putri; Anggindita Diah Widihidayati

[View Article](#) [PDF 511.1 K](#)

6. Mobile Health Interventions for Improving Colorectal Cancer Screening Rates: A Systematic Review and Meta-Analysis

Pages 3093-3099

Anton Elepaño; Alyssa Samantha Fusingan; Eric Yasay; Jereel Aron Sahagun

[View Article](#) [PDF 1.14 MB](#)

7. Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review

Pages 3101-3107

Raden Indra Tresnanda; Sawkar Vijay Pramod; Ferry Safriadi

[View Article](#) [PDF 372.68 K](#)

8. Periodontitis as a Risk Factor for Breast Cancer – What We Know Till Date?

Pages 3109-3114

Rakhi Issrani; RC Jagat Reddy; Tarek H El-Metwally; Namdeo Prabhu

[View Article](#) [PDF 272.93 K](#)

9. A Google Trends™ Analysis of Bladder Cancer: Determining Awareness Campaign Success, and Patients' Needs in Clinical Management

Pages 3115-3120

Aykut Demirci; Berat Cem Özgür

[View Article](#) [PDF 338.29 K](#)

10. Assessment of the Risk of Breast Cancer Development Applying NCI Tool among Iraqi Women

Pages 3121-3126

Zainab Abbas Al Talebi; Seenaa Kadhum Ali; Zinah Kadhim Kareem; Dhafer A.F Al-Koofee

[View Article](#) [PDF 296.02 K](#)

[View Article](#) [PDF 344.62 K](#)**21. p16INK4A Expression in Condyloma Acuminata Lesions Associated with High-Risk Human Papillomavirus Infection**

Pages 3219-3225

Gondo Mastutik; Alphania Rahniayu; Afria Arista; Dwi Murtiastutik; Nila Kurniasari; Trisniartami Setyaningrum; Anny Setijo Rahaju; Erna Sulistyani

[View Article](#) [PDF 452.75 K](#)**22. Lactate Dehydrogenase Levels in the Saliva of Cigarette and E-Cigarette Smokers (Vapers): A Comparative Analysis**

Pages 3227-3235

Anitha Krishnan Pandarathodiyil; Anand Ramanathan; Ranjana Garg; Jennifer Geraldine Doss; Fazliny Binti Abd Rahman; Wan Maria Nabillah Ghani; Saman Warnakulasuriya

[View Article](#) [PDF 390.06 K](#)**23. CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome**

Pages 3237-3243

Noura Fathy El-Metwaly; Salah Aref; Mohamed Ayed; Manal Abdel Hamid; Ahmed M.A El-Sokkary

[View Article](#) [PDF 376.96 K](#)**24. Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype**

Pages 3245-3251

Ismael F Al-Arbeed; Abdulsamad Wafa; Faten Moassass; Bassel AL-Halabi; Walid Al-Achkar; Imad Abou-Khamis

[View Article](#) [PDF 356.88 K](#)**25. Patient Satisfaction with Private Genetic Counselling for Familial Cancer in Western Australia: A Prospective Audit**

Pages 3253-3259

Charmi N Perera; Sarah O'Sullivan; Nicholas Pachter; Jason Jit-Sun Tan; Paul A Cohen

[View Article](#) [PDF 300.85 K](#)**26. Evaluation of PathTezt™, a Liquid-Based Cytology System**

Pages 3261-3266

Nur Syuhada Mohd Nafis; Anani Aila Mat Zin

[View Article](#) [PDF 538.11 K](#)**27. Assessment of the Anti-Cancer Efficiency of Silver Moringa oleifera Leaves Nano-extract against Colon Cancer Induced Chemically in Rats**

Pages 3267-3286

Wael Mahmoud Aboulthana; Wafaa Ghoneim Shousha; Ehab Abdel-Raouf Essawy; Mahmoud Hosny Saleh; Alaa Hamed Salama

[View Article](#) [PDF 1.94 MB](#)**28. Non-Invasive Saliva-based Detection of Gene Mutations in Oral Cancer Patients by Oral Rub and Rinse Technique**

Pages 3287-3291

Audrey D'Cruz; Pandiyanda Nanjappa Dechamma; Marina Saldanha; Sahana Maben; Pushparaja Shetty; Anirban Chakraborty

[View Article](#) [PDF 310.89 K](#)**29. Factors that Affect the Surveillance and Late-Stage Detection of a Newly Diagnosed Hepatocellular Carcinoma**

Pages 3293-3298

Attapon Rattanasupar; Supattra Chartleeraha; Keerati Akarapatima; Arunchai Chang

[View Article](#) [PDF 284.73 K](#)**30. Role of Maspin, CK17 and Ki-67 Immunophenotyping in Diagnosing of Pancreatic Ductal Adenocarcinoma in Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology**

Pages 3299-3307

Mona M Mamdouh; Hussein Okasha; Hebat Allah M Shaaban; Nesreen H Hafez; Emad Hamza El-Gemeic

p16^{INK4A} Expression in Condyloma Acuminata Lesions Associated with High-Risk Human Papillomavirus Infection

Gondo Mastutik^{1*}, Alphania Rahniayu^{1,2}, Afria Arista², Dwi Murtiastutik^{1,2}, Nila Kurniasari^{1,2}, Trisniartami Setyaningrum^{1,2}, Anny Setijo Rahaju^{1,2}, Erna Sulistyani³

Abstract

Objective: The objective of this study was to discover the possible correlation between p16^{INK4A} expression and the LR/HR-HPV infection in condyloma acuminata (CA) lesions. **Materials and Method:** This cross-sectional study was conducted during January-December 2017 on 33 CA patients. The expression of p16^{INK4A} was detected by immunohistochemistry (IHC) staining. The positive interpretation was carried out by scoring which score 0 was negative, score 1 was sporadic, score 2 was focal, and score 3 was diffuses. The HPV genotypes were identified by reverse line blot, and 40 genotypes of HPV detected, including HR-HPV (HPVs 16, 18, 26, 31, 33,35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68a, 68b, 69, 73, and 82) and LR-HPV (HPVs 6, 11, 40, 42, 43, 44, 54, 55, 61, 62, 64, 70, 71, 72, 81, 83, 84, 87, 89, and 90). **Results:** The expression of p16^{INK4A} was significantly correlated with HR-HPV infection. Patients infected with HR-HPV had 0.644 times higher possibility to express p16^{INK4A} gene compared to those infected with LR-HPV. LR-HPV genotypes detected in CA patients were HPVs 6, 11, 42, 61, 54, 81, 87, 89, and 90 and HR-HPV genotypes were HPVs 18, 26, 45, 51, 52, 67, 68B, 69, and 82. LR-HPV was found in 19/33 of patients and HR-HPV was in 14/33 of patients. The expression of p16^{INK4A} in CA lesions was diffuse in 15.2% of patients, was focal in 24.2% of patients, was sporadic in 39.4% of patients, and was negative in 21.2% of patients. In LR-HPV group, there was no diffuse expression, focal expression was observed in 15.8%, sporadic in 47.4%, and negative in 36.8%, while in HR-HPV group, p16^{INK4A} expression was detected in all lesions, in a way that its expression was diffuse in 35.7%, focal in 35.7%, and sporadic in 28.6%. **Conclusion:** IHC is a routine method in histopathological diagnosis, therefore the detection of p16^{INK4A} expression by IHC can be used as a biomarker for HR-HPV infection diagnosis.

Keywords: p16^{INK4A}- high-risk HPV- low-risk HPV- condyloma- sexually transmitted diseases

Asian Pac J Cancer Prev, 22 (10), 3219-3225

Introduction

Condyloma acuminata (CA) is the most frequent sexually transmitted disease worldwide (Santegoets et al., 2012). It is also known as genital warts or anogenital warts. These lesions are usually single or multiple appearing in the anogenital region and causing symptoms of itching, vaginal discharge, and bleeding. CA can be flat or lobulated and appears as pearl-like, filiform, plaque eruption, or cauliflower projection (Patel et al., 2013; Léonard et al., 2014). Its prevalence is increasing worldwide. The prevalence of CA in Italian female population during 2009-2010 was 3.8 cases per 1,000 women per year (Suligoj et al., 2017), in the UK population during 2010-2012 was 3.8% in males and 4.6% in females (Sonnenberg et al., 2019), and in the US population during 2013-2014 was 2.9% (Daugherty et al.,

2018). A systematic review on the incident of anogenital warts showed that their prevalence ranged from 160 to 289 per 100,000 persons. New incident of anogenital warts ranged from 103 to 168 per 100,000 persons among males and 76 to 191 per 100,000 persons among females (Patel et al., 2013).

The most common cause of CA is Human Papillomavirus (HPV). There are two groups of HPV, including high risk (HR) HPV and low risk (LR) HPV. HR-HPV are HPV genotypes of 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 61, 73, and 82, and LR-HPV are HPV genotypes of 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, and 81 (Braaten et al., 2008; Gutiérrez-Xicoténcatl et al., 2009). LR-HPV causes CA, but a study in China showed that the infection of HR-HPV was also found in CA lesions. In some cases, CA is caused by the combination of LR and HR-HPV infections (Lu et al., 2014). Persistent

¹Department of Anatomic Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. ²Department of Dermatology and Venereology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. ³Department of Oral Medicine, Faculty Dentistry, Jember University, Jember, Indonesia *For Correspondence: gondomastutik@fk.unair.ac.id

infection of LR or HR-HPV is a risk factor for the transformation of epithelial to benign hyperplasia or premalignant lesions. HR-HPV is related to the occurrence of malignancy in women, as cervical cancer (Santegoets et al., 2012). Some literature considers HR-HPV as the main causative agent responsible for the cervical cancer (Braaten et al., 2008). The detection of HPV genotype is very important to prevent, establish early diagnosis, and initiate the treatment in cervical cancer. Determination of LR or HR-HPV in anogenital warts can be used as a factor to predict the progression of lesions to benign or malignant lesions.

The E7 HPV protein plays a role in the cell transformation process. It binds to important proteins, such as the pRB and cyclin A/CDK2 complex, inhibiting the interaction between Rb and E2F. The E7 protein of HR-HPV deactivates pRB, resulting in the accumulation of p16^{INK4A} protein. The expression of p16^{INK4A} can also be considered as a marker of E7 gene activity (Izadi-Mood et al., 2012; Romagosa et al., 2011). p16^{INK4A} plays a role in cell cycle regulation and it is involved in the processes of apoptosis, angiogenesis, cell invasion. This activity may be associated with overexpression in cancer (Romagosa et al., 2011). The expression of p16^{INK4A} is a marker to determine the prognosis of a malignancy caused by HPV infection (Missaoui et al., 2010), suggesting that p16^{INK4A} can be a specific marker for HPV infection and may correlate with the type of HR-HPV or LR-HPV. The objective of this study was to analyze the correlation between p16^{INK4A} expression and the LR-HPV or HR-HPV in CA lesions. This study identified the genotype of HPV and performed immunohistochemical analysis of p16^{INK4A} staining of.

Materials and Methods

The samples collection

This cross-sectional study was conducted at Outpatient Clinic of Department Dermatology and Venereology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia, from January 2017 to December 2017. The study was ethically approved by the Medical Ethic Research at Dr. Soetomo General Academic Hospital, Surabaya (ethical code: 382/Panke.KKE/V/2016).

All patients with CA, both male and female, who were willing to participate in the study, were included. Informed consent was obtained from the participants. Menstruating and pregnant women, those who suffered from an active pelvis and / or acute cervicitis, men or women with a diagnosis of HIV and AIDS, and those who were not willing to participate in the study were excluded.

The specimens were 33 tissues of CA. Tissue from each patient was divided into 2 parts, one part for tissue processing into paraffin block preparations followed by histopathological diagnosis and immunohistochemistry (IHC) staining, while another for the examination of the HPV genotype. Histopathological diagnosis of CA and analysis of IHC staining was performed by a pathologist.

Expression of p16^{INK4A}

The expression of p16^{INK4A} was detected by

IHC staining using Anti-CDKN2A/ p16^{INK4A} Antibody (clone 1E12E10) IHC-plus™ LS-B5261 (LS Bio). The interpretation was positive if cells were stained in the nucleus or combined in the nucleus and cytoplasm. The assessment was carried out based on guidelines presented by Klaes et al. (2001) as follows:

Score 0 (negative): if cells were stained positive <1% of all cells

Score 1 (sporadic): if cells were stained positive <5% of all cells

Score 2 (focal): if cells were stained positive <25% of all cells

Score 3 (diffuses): if cells were stained positive > 25% of all cells.

Genotyping of HPV

Virus extraction was carried out from CA tissues using the QIAamp DNA Mini Kit (Qiagen) kit and according to the manufacturer's protocol. Genotyping of HPV was performed by Polymerase Chain Reaction (PCR), then followed by reverse line blot using the Ampliquality HPV type express v 3.0 kit (Ab Analitica). This kit could detect 40 genotypes of HPV, including HR-HPV were HPV 16, 18, 26, 31, 33,35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68 (68a, 68b), 69, 73, and 82 and LR-HPV were HPV 6, 11, 40, 42, 43, 44, 54, 55, 61, 62, 64, 70, 71, 72, 81, 83, 84, 87, 89, and 90.

Statistical analysis

The difference in the expression of p16^{INK4A} on CA patients with HR-HPV or LR-HPV groups infection was analyzed by Mann Whitney test (significant if $p < 0.05$). The correlation between variables was analyzed by two-tailed Spearman's rho (significant if $p < 0.05$).

Results

Characteristics of patient

This study was performed on 33 patients suffering from CA. Patients' characteristic, such as sex, age, sexual partner, duration of the symptoms, medical history, presence of lesion in the partner, history of treatment, and shape, type, and location of the lesion were investigated. The patients consisted of 12 (36.4%) males and 21 (63.6%) females. The patients aged from 18 to 64 years. The highest frequency was allocated to the age group of 15-24 years old (51.5%). Regarding sexual partner, it was found that 30/33 of the patients (90.9%) were heterosexual (men having sex with women), 2/33 (6.1%) were bisexual (having sex with the same and different sex), and 1/33 (3.0%) were homosexual (having sex with the same sex). Regarding symptoms duration, the highest frequency was allocated to the duration of 1 to 3 months. Mostly, the patients experienced CA for the first time, there was no lesion in their partner, and received TCA therapy, respectively. Considering the shape, type, and location of the lesion, it was revealed that the highest frequencies were allocated to papule shape, multiple type of lesions, and gland penis for male and labia majora for female (Table 1).

HPV genotype in CA lesions




Figure 1. The Histopathological Feature and p16^{INK4A} Expression of Condyloma Acuminata. A, Condyloma acuminata from HR-HPV infected patients, in HE staining (40 x magnification); B, In the same patients, p16^{INK4A} expression showed in diffuse (score 3) (40 x magnification); C, Condyloma acuminata from LR-HPV infected patients, in HE staining (40 x magnification); D, In the same patients, p16^{INK4A} expression showed negative (score 0) (40 x magnification); E, p16^{INK4A} expression in negative (score 0) (400 x magnification); F, p16^{INK4A} expression in diffuse (score 3) (400 x magnification).

The genotype of HPV included the infection of HPV-HR and LR, both single and multiple infections. The single or multiple infections of HPV-LR was assumed as infection of LR-HPV. The multiple infection of LR-HPV with HR-HPV was assumed as infection of HR-HPV. The genotype of LR-HPV were HPV 6, 11, 42, 61, 54, 81, 87, 89, and 90, and of HR-HPV were 18, 26, 45, 51, 52, 67, 68B, 69, and 82. LR-HPV was found in 19/33 (57.6%) of the patients and HR-HPV was seen in 14/33 (42.4%) of the patients (Table 2). The most dominant HPV was HPV 11 that infected 24/56 (42.9%) times more, then followed by HPV 6 (16.1%) and HPV 18, HPV 51, and HPV 82 for 5.4%, respectively.

p16^{INK4A} expression in CA lesions

The expression of p16^{INK4A} in CA lesions showed that nucleus or the combination of nucleus and cytoplasm of cell was stained in brown color, indicating in sporadic, focal, or diffuse (Figure 1). The results showed that 7/33 (21.2%) of the lesions were negative, 13/33 (39.4%) were sporadic, 8/33 (24.2%) were focal, and 5/33 (15.2%)

were diffuse. In LR-HPV group, the results showed that negative, sporadic, and focal lesions were 7/19 (36.8%), 9/19 (47.4%), and 3/19 (15.8%), respectively. In HR-HPV group, it was found that the frequency of sporadic lesions was 4/14 (28.6%), focal was 5/14 (35.7%), and diffuse was 5/14 (35.7%) (Table 3). There was a significant different between LR-HPV and HR-HPV groups in terms of p16^{INK4A} expression in CA lesion ($p = 0,000$). Correlation between p16^{INK4A} expression and LR-HPV and HR-HPV infections was moderate ($r = 0,644$, $p = 0,000$).

Discussion

The microscopic features of CA lesions based on haematoxylin eosin (HE) staining are parakeratosis, hyperkeratosis, hypergranulosis, basal cell hyperplasia, and koilocytic (Léonard et al., 2014). In this study, CA lesions were seen as papules, cauli flowers, and flat-tapping papules. The microscopic features found in this study were hyperkeratosis, parakeratosis, papillomatosis, hypergranulosis, and hyperplasia of basal

Table 1. Characteristics of Patients with Condyloma Acuminata

Characteristics of Patients	N (%)	Single or multiple infection LR/LR HPV N (%)	Multiple infection of LR/HR HPV N (%)
Sex			
Male	12 (36.4)	7 (21.2)	5 (15.1)
Female	21 (63.6)	12 (36.4)	9 (27.3)
Age			
15-24 years	17 (51.5)	10 (30.3)	7 (21.2)
25-34 years	6 (18.2)	3 (9.1)	3 (9.1)
35-44 years	7 (21.2)	4 (12.1)	3 (9.1)
45-54 years	2 (6.1)	1 (3.0)	1 (3.0)
55-64 years	1 (3.0)	1 (3.0)	0
Sexual Partner			
Heterosexuals	30 (90.9)	18 (54.5)	12 (36.4)
Homosexual	1 (3.0)	1 (3.0)	0
Bisexual	2 (6.1)	0	2 (6.1)
Duration of symptom			
< 1 month	5 (15.1)	1 (3.0)	4 (12.1)
1- 3 months	20 (61.6)	14 (42.4)	6 (18.2)
4 - 6 months	6 (18.2)	3 (9.1)	3 (9.1)
> 6 months	2 (6.1)	1 (3.0)	1 (3.0)
History			
First lesion	26 (78.8)	15 (45.4)	11 (33.3)
Recurrent lesion	7 (21.2)	4 (12.1)	3 (9.1)
Lesion on the partner			
Have lesion on the partner	4 (12.1)	2 (6.1)	2 (6.1)
No lesions on the partner	29 (87.9)	17 (51.5)	12 (36.4)
Therapy			
TCA	19 (57.6)	11 (33.3)	8 (24.2)
Cautery	14 (42.4)	8 (24.2)	6 (18.2)
Shape			
Papule	28 (84.8)	16 (48.5)	12 (36.4)
Cauli flower	4 (12.1)	2 (6.1)	2 (6.1)
Flat tapped papule	1 (3.0)	1 (3.0)	0
Type			
Multiple	31 (93.9)	18 (54.5)	13 (39.4)
Solitary	2 (6.1)	1 (3.0)	1 (3.0)
Location			
Penile	7 (21.2)	4 (12.1)	3 (9.1)
Anus	4 (12.1)	2 (6.1)	2 (6.1)
Penile and anus	1 (3.0)	1 (3.0)	0
Labia (majora and minora)	16 (48.5)	10	6 (18.2)
Vulva	3 (9.1)	1 (3.0)	2 (6.1)
Introitus vagina	1 (3.0)	0	1 (3.0)
Perineum	1 (3.0)	1 (3.0)	0

cell, as well as the koilocytes that usually is associated with HPV infection.

The most common cause of CA is infection by HPV. There are more than 40 genotypes of HPV that can infect the anogenital area that are usually infected by LR-HPV including HPV 6 and HPV 11 in single infection, but most commonly co-infection with LR-HPV or HR-HPV

(Léonard et al., 2014; Hasanzadeh et al., 2019). The results of this study showed that all the tissues taken from the patients, who were clinically diagnosed with CA, were positive for LR-HPV or HR-HPV infections, in single infection or multiple infection. Most of the patients were infected by LR-HPV, while 42.4% were infected by LR-HPV and co-infected with HR-HPV. In line with this

Table 2. Distribution of HPV in Condyloma Acuminata Lesions

Genotype of HPV	HR or LR HPV genotypes	Frequency N (%)
LR HPV		
HPV 6	LR	4
HPV 11	LR	12
HPV 6, 11	LR	2
HPV 6,81,87,89	LR	1
HR HPV		
HPV 6,11,18,51,82	HR	1
HPV 6,42,51,61	HR	1
HPV 11, 18	HR	2
HPV 11,18,45	HR	1
HPV 11, 26	HR	1
HPV 11,67	HR	1
HPV 11, 51, 82	HR	1
HPV 11, 52, 54	HR	1
HPV 11, 52,69,90	HR	1
HPV 11, 68B	HR	1
HPV 11, 82	HR	2
Total		33

study, a cross-sectional study in Kuwait on 156 patients with genital warts showed that 102/156 (65.4%) of the patients were infected by LR-HPV and 54/156 (34.6%) of the patients were infected by HR-HPV. About 88.4% of the patients in the aforementioned study had single infection and 11.6% had multiple infections (Al-Awadhi et al., 2019). Another study in Spain showed that the frequency of LR-HPV infection was 63/138 (45.6%) in their patients and 71/138 (41.4%) of anogenital warts patients were infected by HR-HPV (Arroyo et al., 2016). The other study on 66 anogenital warts specimens showed that LR-HPV infected 42/66 (62.1%) which was dominated by HPV 6 (47%), and HPV-11 (13.6%), as well as HPV 18 and HPV 3 (Ozaydin-Yavuz et al., 2019). We discovered that that beside LR-HPV, CA was also co-infected with HR-HPV that could develop to malignant cancer. Therefore, identification of HPV genotype can predict the risk of developing related diseases. In addition, determination of HPV genotype affects treatment management, patients' follow-up, and prevention strategies

The findings of this study revealed that 57.6% of CA patients were infected by LR-HPV and the rest were

infected by both LR-HPV and HR-HPV infections. The most common HPV genotypes were HPV 11 and HPV 6 for LR-HPV, followed by HPV 18, HPV 51, and HPV 82 for HR-HPV. The incidence of CA and the progression of the disease can be prevented by vaccination. Recently, there are 3 commercial vaccines against HPV infection, namely Gardasil to prevent infections caused by HPV 6, 11, 16, and 18, Cervarix to prevent infections caused by HPV 16, and 18, and Gardasil 9 to prevent infections caused by HPV 6, 11, 61, 18, 31, 33, 45, 52, and 58 (Gupta et al., 2017). A previous study on anogenital benign lesions showed that HPV genotype in CA patients was dominated by HPV 11 and HPV 6 among 13 female patients (Arista et al., 2019) and 12 male patients (Murtiastutik et al., 2019). In pre-cancerous lesion and cancerous lesion of uterine cervix, those were dominated by HPV 16 (62.68%), then followed by HPV 18 (20.9%), HPV 45 (5.97%), HPV 52 (5.97%), and HPV 67 (4.48%) (Mastutik et al., 2018). Vaccination programs is expected to reduce the incidence of these diseases, but there are some genotypes of HPV that cannot be targeted by the current vaccines. Therefore, strategies to prevent the incidence of CA or the progression of malignancy still need to be developed.

Oncoprotein E6 and E7 of HR-HPV play a role in cancer development. HR-HPV E6 mediates p53 inactivation by binding to the conserved domains of E6AP (E6-linked protein) to form the E6/ E6AP/p53 complex. This complex causes degradation of p53 by ubiquitination mechanism. HR-HPV E7 targets to degrade the retinoblastoma protein (pRB). In normal cells, when cells are prevented from entering the S phase, the pRB binds to the E2F family of transcription factor, so that the cell stops at the checkpoint of G1-S phase, activating cell cycles arrest. pRb, which is phosphorylated by cyclin D1/CDK 4/6 complex, causes E2F to be released and enter the nucleus. The cell enters the S phase which then starts the activation of gene transcription (Munger et al., 2013, Pal and Kudu, 2020). Furthermore, phosphorylated pRB is a p16^{INK4A} feedback mechanism. HPV E7 induces degradation of pRB by an ubiquitin proteasome pathway that causes the loss feedback mechanism of p16^{INK4A} and then leads to accumulation of p16^{INK4A}, presenting as overexpression of p16^{INK4A} (Lassen et al., 2009; Faraji et al., 2017).

The overexpression of p16^{INK4A} in this study was sporadic (39.4%), focal (24.2%), diffuse (15.2%), and negative (21.2%). Another study on p16^{INK4A} expression in 24 CA specimens showed that overexpression of p16^{INK4A} were sporadic in 11/24 of the specimens (45.8%),

Table 3. The p16^{INK4A} Expression on Condyloma Acuminata that Infected by LR or HR-HPV

p16 ^{INK4A} expression	HPV genotype		Total N (%)	p-value
	LR-HPV N (%)	LR/HR-HPV N (%)		
Score 0 (Negative)	7 (36.8)	0 (0)	7 (21.2)	0.000*
Score 1 (Sporadic)	9 (47.4)	4 (28.6)	13 (39.4)	
Score 2 (Focal)	3 (15.8)	5 (35.7)	8 (24.2)	
Score 3 (Diffuse)	0 (0)	5 (35.7)	5 (15.2)	
Total	19 (100)	14 (100)	33 (100)	

*Mann Whitney, Asymptotic Significance (2-tailed) with p = 0,000 (p < 0,05); Correlation is significant at the 0.01 level (2-tailed) with Spearman's rho (r) = 0,644, p = 0,000

were focal in 7/24 of the specimens (29.2%), and were negative in 6/24 of the specimens (25%) (Kazlouskaya et al., 2013). The expression of p16^{INK4A} in cervix tended to increase from cervical normal epithelium to invasive cervical cancer (Missaoui et al., 2010; Izadi-Mood et al., 2012) and cervical adenocarcinoma (Mastutik et al., 2021). The expression of p16^{INK4A} in HR-HPV showed that all specimens were positive ranging from sporadic to diffuse. In LR-HPV were sporadic and focal, whereas 36.8% of specimens were not expressed in p16^{INK4A} and none of specimens expressed in diffuse category. Other study on anal lesion with HR HPV infection showed that all specimens expressed p16^{INK4A} ranging from sporadic to diffuse, whereas those infected with LR-HPV were mostly patchy (Leeman et al., 2019). In oropharyngeal squamous cell carcinomas and tonsillar dysplasia that were positive for HPV 16, p16^{INK4A} expression was also diffuse. However, in benign and pre-malignant lesions were positive for HPV 6 and HPV 11 showed variations from negative to strong positive (Mooren et al., 2014). All cervical lesions infected with HR-HPV had a significant, strong, and diffuse p16^{INK4A} expression, whereas those infected with LR-HPV showed mild p16^{INK4A} expression (score 1) (Missaoui et al., 2014).

These findings highlighted that the expression of p16^{INK4A} significantly correlated with HR-HPV infection, in a way that CA lesions infected by HR-HPV had 0.644 times more chances to express p16^{INK4A} compared to CA lesions infected by LR-HPV. As previous studies showed that p16^{INK4A} expression was associated with HR-HPV infection in oropharyngeal squamous (Liu et al., 2015), mucosal squamous cell carcinomas of the head and neck (Antonsson et al., 2015), cervical squamous intraepithelial lesion (Yildiz et al., 2007), and invasive cervical and vaginal carcinomas (Missaoui et al., 2010; Missaoui et al., 2014). HR-HPV is integrated into the host cell genome, whereas LR-HPV prefers extra chromosome as episome, so that the expression of E6 and E7 oncoproteins are within the regulatory framework of E1 and E2 HPV (Boulet et al., 2007). HR-HPVs, such as HPV 18, 33, HPV 51, HPV 58, and HPV 59, were found to be integrated, while HPVs 30, 35, 39, 44, 45, 53, 56, 59, 74 and 82 did not tend to be integrated, but to be in episome form (Nkili-Meyong et al., 2019). In this study, it was found that HR-HPVs 18, 51, and 82. As reported by Nkili-Meyong et al., (2019), HPV 18 was founded to be integrated in 55% of the positive HPV 18 specimen, HPV 51 was integrated in 25% of the positive HPV 51 specimen, and HPV 82 was founded in extra chromosome. This integration was associated with partial or total deletion of E1 and E2 genes, leading to the overexpression of E6 and E7 due to loss of feedback mechanism by E2 protein (Woodman et al., 2007; Nkili-Meyong et al., 2019). In addition, the HR-HPV E7 oncoproteins have higher affinity to bind pRB than LR-HPV E7, increasing the accumulation of p16^{INK4A}. Therefore, all specimens infected by HR-HPV in this study were positive for the expression of p16^{INK4A} in sporadic, focal, and diffuse forms, while those infected by LR-HPV had sporadic and focal, but not diffuse expression.

In conclusion, this study found significant differences between CA specimens infected by LR-HPV (HPV 6, 11,

42, 61, 54, 81, 87, 89, 90) and HR-HPV (HPV 18, 26, 45, 51, 52, 67, 68B, 69, 82) regarding the expression of p16^{INK4A}. p16^{INK4A} expression was correlated with HR-HPV infection moderately. IHC is a routine method to perform the diagnostic of histopathological. Therefore, IHC of p16^{INK4A} could be used as biomarker for HR-HPV infection to predict the malignancy development of CA lesions.

Author Contribution Statement

Concepts, design, definition of intellectual content: Gondo Mastutik. Literature search: Gondo Mastutik, Afria Arista. Clinical studies: Gondo Mastutik, Dwi Murtiastutik, Trisniartami Setyaningrum. Experimental studies: Gondo Mastutik, Alphania Rahniayu, Afria Arista. Data acquisition: Nila Kurniasari, Alphania Rahniayu, Anny Setijo Rahaju. Data analysis: Gondo Mastutik, Alphania Rahniayu, Anny Setijo Rahaju. Statistical analysis: Gondo Mastutik, Nila Kurniasari, Anny Setijo Rahaju. Manuscript preparation and manuscript editing: Gondo Mastutik, Afria Arista, Anny Setijo Rahaju. Manuscript review: Gondo Mastutik, Alphania Rahniayu, Dwi Murtiastutik, Trisniartami Setyaningrum, Erna Sulistyani.

Acknowledgement

We are thankful of Government of the Republic of Indonesia, the Ministry of Research, Technology and Higher Education, and the Faculty of Medicine, Airlangga University for funding in this research with the university's operational funding for the 2017 fiscal year.

Funding statement

This study was supported by the Faculty of Medicine, Airlangga University, and the university's operational funding for the 2017 fiscal year. This manuscript have not been presented at a scientific event or submitted to any other journals.

Ethical statement

Ethical study was approved by the Medical Ethic Research at Dr. Soetomo General Academic Hospital Surabaya, Indonesia (ethical code:382/Panke. KKE/V/2016).

Statement conflict of interest

The authors declare no conflict of interest


References


- Al-Awadhi R, Al-Mutairi N, Albatineh AN, Chehadeh W (2019). Association of HPV genotypes with external anogenital warts: a cross sectional study. *BMC Infect Dis*, **19**, 375-82.
- Antonsson A, Neale RE, Boros S, et al (2015). Human papillomavirus status and p16(INK4A) expression in patients with mucosal squamous cell carcinoma of the head and neck in Queensland, Australia. *Cancer Epidemiol*, **39**, 174-81.
- Arista A, Murtiastutik D, Setyaningrum T, Mastutik G (2019). Genotyping of Human Papilloma Virus (HPV) in female condyloma acuminata patient in Dr. Soetomo Hospital, Surabaya. *Dermatol Rep*, **11**, 122-3.

- Arroyo LS, Basaras M, Arrese E, et al (2016). Distribution of genital human papillomavirus genotypes in benign clinical manifestations among men from Northern Spain. *BMC Public Health*, **16**, 81-8.
- Boulet G, Horvath C, Vanden Broeck D, Sahebali S, Bogers J (2007). Human papillomavirus: E6 and E7 oncogenes. *Int J Biochem Cell Biol*, **39**, 2006-11.
- Braaten KP, Laufer MR (2008). Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine. *Rev Obstet Gynecol*, **1**, 2-10.
- Daugherty M, Byler T (2018). Genital Wart and Human Papillomavirus Prevalence in Men in the United States From Penile Swabs: Results From National Health and Nutrition Examination Surveys. *Sex Transm Dis*, **45**, 412-6.
- Faraji F, Zaidi M, Fakhry C, Gaykalova DA (2017). Gaykalova DA. Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer. *Microbes Infect*, **19**, 464-75.
- Gupta G, Glueck R, Patel PR (2017). HPV vaccines: Global perspectives. *Hum Vaccin Immunother*, **13**, 1421-24.
- Gutiérrez-Xicoténcatl L, Plett-Torres T, Madrid-González CL, Madrid-Marina V (2009). Molecular diagnosis of human papillomavirus in the development of cervical cancer. *Salud Publica Mex*, **51**, S479-88.
- Hasanzadeh M, Rejali M, Mehramiz M, et al (2019). The interaction of high and low-risk human papillomavirus genotypes increases the risk of developing genital warts: A population-based cohort study. *J Cell Biochem*, **120**, 12870-4.
- Izadi-Mood N, Asadi K, Shojaei H, et al (2012). Potential diagnostic value of P16 expression in premalignant and malignant cervical lesions. *J Res Med Sci*, **17**, 428-33.
- Kazlouskaya V, Shustef E, Allam SH, Lal K, Elston D (2013). Expression of p16 protein in lesional and perilesional condyloma acuminata and bowenoid papulosis: clinical significance and diagnostic implications. *J Am Acad Dermatol*, **69**, 444-9.
- Klaes R, Friedrich T, Spitkovsky D, et al (2001). Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. *Int J Cancer*, **92**, 276-84.
- Lassen P, Eriksen JG, Hamilton-Dutoit S, et al (2009). Effect of HPV-associated p16^{INK4A} expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. *J Clin Oncol*, **27**, 1992-8.
- Leeman A, Jenkins D, Marra E, et al (2019). Grading immunohistochemical markers p16^{INK4a} and HPV E4 identifies productive and transforming lesions caused by low- and high-risk HPV within high-grade anal squamous intraepithelial lesions. *Br J Dermatol*, **182**, 1026-33.
- Léonard B, Kridelka F, Delbecq K, et al (2014). A clinical and pathological overview of vulvar condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinoma. *Biomed Res Int*, **2014**, 1-11.
- Liu SZ, Zandberg DP, Schumaker LM, Papadimitriou JC, Cullen KJ (2015). Correlation of p16 expression and HPV type with survival in oropharyngeal squamous cell cancer. *Oral Oncol*, **51**, 862-9.
- Lu LH, Yu J, Zhang YH, Wu XF, Liu XY (2014). HPV Infection and Distribution of HPV Genotypes on Patients with Condyloma Acuminatum. *J Reproduct Contraception*, **25**, 26-31.
- Mastutik G, Alia R, Rahniayu A, et al (2018). Genotyping of human papillomavirus in cervical precancerous lesion and squamous cell carcinoma at Dr. Soetomo Hospital, Surabaya, Indonesia. *Afr J Infect Dis*, **12**, 7-12.
- Mastutik G, Rahniayu A, Kurniasari N, Rahaju AS, Alia R (2021). Correlation between the expression of E6 HPV with P53 and P16^{INK4A} at cervical adenocarcinoma and cervical normal. *Indian J Forensic Med Toxicol*, **15**, 1827-34.
- Missaoui N, Trabelsi A, Hmissa S, et al (2010). p16^{INK4A} overexpression in precancerous and cancerous lesions of the uterine cervix in Tunisian women. *Pathol Res Pract*, **206**, 550-5.
- Missaoui N, Abdelkarim SB, Mokni M, Hmissa S (2014). p16^{INK4A} expression in squamous cell carcinomas of the vagina and the vulva in Tunisian women. *Asian Pac J Cancer Prev*, **15**, 10803-8.
- Mooren JJ, Gültekin SE, Straetmans JM, et al (2013). P16(INK4A) immunostaining is a strong indicator for high-risk-HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-HPV-infection in head and neck papillomas and laryngeal dysplasias. *Int J Cancer*, **134**, 2108-17.
- Munger K, Gwin TK, McLaughlin-Drubin ME (2020). p16 in HPV-associated cancers. *Oncotarget*, **4**, 1864-5.
- Murtiastutik D, Mastutik G, Rahniayu A, Arista A, Setyaningrum T (2019). The Genotype of Human Papilloma Virus of Male Patients with Anogenital Warts. *Folia Med Indonesiana*, **55**, 100-6.
- Nkili-Meyong AA, Moussavou-Boundzanga P, Labouba I, et al (2019). Genome-wide profiling of human papillomavirus DNA integration in liquid-based cytology specimens from a Gabonese female population using HPV capture technology. *Sci Rep*, **9**, 1504-14.
- Ozaydin-Yavuz G, Bilgili SG, Guducuoglu H, et al (2019). Determinants of high-risk human papillomavirus infection in anogenital warts. *Postepy Dermatol Alergol*, **36**, 76-81.
- Pal A, Kundu R (2020). Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. *Front Microbiol*, **10**, 1-15.
- Patel H, Wagner M, Singhal P, Kothari S (2013). Systematic review of the incidence and prevalence of genital warts. *BMC Infect Dis*, **13**, 39-52.
- Romagosa C, Simonetti S, López-Vicente L, et al (2011). p16(INK4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. *Oncogene*, **30**, 2087-97.
- Santegoets LA, van Baars R, Terlou A, et al (2012). Different DNA damage and cell cycle checkpoint control in low- and high-risk human papillomavirus infections of the vulva. *Int J Cancer*, **130**, 2874-85.
- Sonnenberg P, Tanton C, Meshier D, et al (2019). Epidemiology of genital warts in the British population: implications for HPV vaccination programmes. *Sex Transm Infect*, **95**, 386-90.
- Suligoï B, Vittori G, Salfa MC, et al (2017). Prevalence and incidence of external genital warts in a sample of Italian general female population. *BMC Infect Dis*, **17**, 126-33.
- Woodman CB, Collins SI, Young LS (2007). The natural history of cervical HPV infection: unresolved issues. *Nat Rev Cancer*, **7**, 11-22.
- Yildiz IZ, Usubütün A, Firat P, Ayhan A, Küçükali T (2007). Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. *Pathol Res Pract*, **203**, 445-9.



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.

<p>COUNTRY</p> <p>Thailand</p> <p> Universities and research institutions in Thailand</p>	<p>SUBJECT AREA AND CATEGORY</p> <p>Biochemistry, Genetics and Molecular Biology</p> <ul style="list-style-type: none"> Cancer Research <p>Medicine</p> <ul style="list-style-type: none"> Epidemiology Oncology Public Health, Environmental and Occupational Health 	<p>PUBLISHER</p> <p>Asian Pacific Organization for Cancer Prevention</p>	<p>H-INDEX</p> <p>80</p>
<p>PUBLICATION TYPE</p> <p>Journals</p>	<p>ISSN</p> <p>15137368</p>	<p>COVERAGE</p> <p>2000-2021</p>	<p>INFORMATION</p> <p>Homepage</p> <p>How to publish in this journal</p> <p>rmosavi@yahoo.com</p>





Source details

Asian Pacific Journal of Cancer Prevention

Open Access ⓘ

Scopus coverage years: from 2000 to Present

Publisher: Asian Pacific Organization for Cancer Prevention

ISSN: 1513-7368

Subject area: Medicine: Public Health, Environmental and Occupational Health Medicine: Epidemiology Medicine: Oncology

Biochemistry, Genetics and Molecular Biology: Cancer Research

Source type: Journal

CiteScore 2021 ⓘ

3.1

SJR 2021 ⓘ

0.464

SNIP 2021 ⓘ

0.814

[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ▼

$$3.1 = \frac{6,446 \text{ Citations 2018 - 2021}}{2,072 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$2.6 = \frac{4,782 \text{ Citations to date}}{1,841 \text{ Documents to date}}$$

Last updated on 05 September, 2022 • Updated monthly

CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Medicine		
Public Health, Environmental and Occupational Health	#242/562	57th
Medicine		
Epidemiology	#65/108	40th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)



**KOMITE ETIK PENELITIAN KESEHATAN
RSUD Dr. SOETOMO SURABAYA**

**KETERANGAN KELAIKAN ETIK
(" ETHICAL CLEARANCE ")**

382 / Panke.KKE / V / 2016

KOMITE ETIK RSUD Dr. SOETOMO SURABAYA TELAH MEMPELAJARI SECARA SEKSAMA RANCANGAN PENELITIAN YANG DIUSULKAN, MAKA DENGAN INI MENYATAKAN BAHWA PENELITIAN DENGAN JUDUL :

"Eksplorasi Tipe Human Pappiloma Virus yang Menginfeksi Penderita Kondiloma Akuminata"

PENELITI UTAMA : Dr. Gondo Mastutik, drh., M.Kes

**PENELITI LAIN : 1. Dwi Murtiastutik, dr., Sp.KK(K)
2. Alphania Rahniayu, dr., Sp.PA
3. Afria Arista, dr**

UNIT / LEMBAGA / TEMPAT PENELITIAN : RSUD Dr. Soetomo Surabaya

DINYATAKAN LAIK ETIK

SURABAYA, 18 MAY 2016
KETUA

(Prof. Hari Sukanto, dr., Sp.KK (K))
NIP. 19471115 1973 03 1 001